European Organisation for Research and Treatment of Cancer (EORTC) shared a post on LinkedIn:
“On the occasion of the European Association of Nuclear Medicine (EANM) Congress, EORTC is proud to highlight its leadership in Radioligand Therapy (RLT) and nuclear medicine.
Through its Radioligand Task Force, European Organisation for Research and Treatment of Cancer is working to generate the clinical evidence needed to support the use of radioligands in oncology.
Key highlights on EORTC studies:
- LUMEN-1: A phase II trial evaluating [177Lu]Lu-DOTATATE in patients with recurrent meningioma.
- RENALUT: Investigating [177Lu]Lu-PSMA-617 in metastatic renal cell carcinoma.
- PEACE III: A landmark trial using radium-223 in combination with Enzalutamide for prostate cancer with bone metastases.
These studies are part of a broader effort to make cancer treatment more precise, effective, and accessible across Europe.
Read our Full Article here.”
More posts featuring the European Organisation for Research and Treatment of Cancer on OncoDaily.